Biotech Archives - Page 44 of 795

3 minute read

Delcath Systems Announces Publication Of Results From Pivotal FOCUS Study In Metastatic Uveal Melanoma Patients Treated With HEPZATO KIT

May 6, 9:03 AM

Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%)Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response RateNEW YORK, May 6, 2024

DCTH

2 minute read

Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?

By Vandana Singh

May 6, 9:00 AM

EyePoint Pharmaceuticals reveals Phase 2 PAVIA trial results for Duravyu in non-proliferative diabetic retinopathy. Positive data showcases Duravyu's efficacy and safety profile.

EYPT

4 minute read

Cybin Provides Corporate Update And Highlights Upcoming Clinical Milestones; Initiation Of Pivotal CYB003 Phase 3 Study In MDD Expected In Mid-2024; Phase 2 Topline Efficacy And Safety Results For CYB004 In Generalized Anxiety Disorder Expected Q4 2024

By Benzinga Newsdesk

May 6, 8:42 AM

- Recent U.S. $150 Million funding round lead by a syndicate of leading biopharmaceutical institutional investors supports advancement of clinical-stage programs CYB003 and CYB004 -- Received U.S. Food and Drug

CYBN

1 minute read

AIM ImmunoTech Completes cGMP Manufacturing Of Clinical Vials Of Ampligen

By Benzinga Newsdesk

May 6, 8:38 AM

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM's dsRNA product candidate being

AIM

3 minute read

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect In Pancreatic Murine Tumor Models At ESTRO 2024 Congress In Glasgow; Initial Data Demonstrates Reduction In Distant Pancreatic Cancer Tumor Growth Rate Starting From 3-Weeks After…

By Benzinga Newsdesk

May 6, 8:37 AM

- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone - Effect seen across both Panc02 and KPC

DRTS

3 minute read

PROCEPT BioRobotics Announces Real-World, Long-Term Data Demonstrate Sustained Benefits Of Aquablation Therapy For Men With Benign Prostatic Hyperplasia

By Benzinga Newsdesk

May 6, 8:22 AM

PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced long-term, real-world

PRCT

4 minute read

Belite Bio Presents Additional Analysis From Phase 2 Study Of Tinlarebant In Stargardt Disease At The ARVO Annual Meeting

By Benzinga Newsdesk

May 6, 8:21 AM

Additional analysis of visual acuity loss, genotypic profiles, and retinal imaging data from a 24-month Phase 2 trial of Tinlarebant in adolescent Stargardt disease patients provides further support for the potential of

BLTE

1 minute read

Biora Therapeutics To Present Clinical Data On Device Function Of The NaviCap Oral Delivery Platform At Digestive Disease Week 2024

By Benzinga Newsdesk

May 6, 8:18 AM

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present clinical data on device function of the NaviCap™ Targeted Oral Delivery

BIOR

3 minute read

EDAP Announces Final Results From The HIFI Study Comparing Outcomes Of Focal One HIFU Versus Radical Prostatectomy During Plenary Session At The 119th American Urological Association Annual Meeting

By Benzinga Newsdesk

May 6, 8:18 AM

Final results demonstrate a significantly higher salvage treatment free survival rate (STFS) at 30 months of 89.6% in the HIFU-treated arm versus 86.2% in patients who

EDAP

2 minute read

Regulus Therapeutics Advances To Cohort 4 Of Phase 1b Multiple-Ascending Dose Clinical Trial Of RGLS8429 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease

By Benzinga Newsdesk

May 6, 8:15 AM

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced, after review of all

RGLS